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Abstract
Background: HIV integrase inhibitor use is limited by low genetic barrier to resistance and possible cross-resistance
among representatives of this class of antiretrovirals. The aim of this study was to analyse integrase sequence
variability among antiretroviral treatment naive and experienced patients with no prior integrase inhibitor (InI)
exposure and investigate development of the InI drug resistance mutations following the virologic failure of the
raltegravir containing regimen.
Methods: Sequencing of HIV-1 integrase region from plasma samples of 80 integrase treatment naive patients and
serial samples from 12 patients with observed virologic failure on raltegravir containing treatment whenever plasma
vireamia exceeded >50 copies/ml was performed. Drug resistance mutations were called with Stanford DB
database and grouped into major and minor variants. For subtyping bootstrapped phylogenetic analysis was used;
Bayesian Monte Carlo Marcov Chain (MCMC) model was implemented to infer on the phylogenetic relationships
between the serial sequences from patients failing on raltegravir.
Results: Majority of the integrase region sequences were classified as subtype B; the remaining ones being subtype
D, C, G, as well as CRF01_AE , CRF02_AG and CRF13_cpx recombinants. No major integrase drug resistance
mutations have been observed in InI-treatment naive patients. In 30 (38.5%) cases polymorphic variation with
predominance of the E157Q mutation was observed. This mutation was more common among subtype B (26
cases, 54.2%) than non-B sequences (5 cases, 16.7%), p=0.00099, OR: 5.91 (95% CI:1.77-22.63)]. Other variants
included L68V, L74IL, T97A, E138D, V151I, R263K. Among 12 (26.1%) raltegravir treated patients treatment failure was
observed; major InI drug resistance mutations (G140S, Q148H and N155H, V151I, E92EQ, V151I, G163R) were noted
in four of these cases (8.3% of the total InI-treated patients). Time to the development of drug resistance ranged
from 2.6 to 16.3 months with mean increase of HIV viral load of 4.34 (95% CI:1.86-6.84) log HIV-RNA copies/ml at
the time of emergence of the major mutations. Baseline polymorphisms, including E157Q were not associated with
the virologic failure on raltegravir.
Conclusions: In InI treatment naive patients polymorphic integrase sequence variation was common, with no
major resistance mutants. In the treatment failing patients selection of drug resistance occurred rapidly and
followed the typical drug resistance pathways. Preexisting integrase polymorphisms were not associated with the
treatment failure.
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Background
HIV integrase, being one of the key retroviral enzymes ne-
cessary for successful replication, is one of attractive tar-
gets in the treatment of HIV infection. Integrase
inhibitors, targeting one of the essential steps of the virus
life cycle, namely strand transfer have been approved for
the clinical practice in 2008, and have proven to be highly
efficient in treatment of both antiretroviral-naive and
experienced individuals [1-6]. As potent agents, this class
of drugs is not only important part of the salvage regimens
but is also useful in patients with therapy complications
such as lipodystrophy, dyslipidaemia, or liver injury [7-9].
Raltegravir (RAL) is currently licensed in Europe for both
treatment naive and experienced patients, elvitregravir
pending EMEA approval, while newer compounds such as
dolutegravir undergo phase III clinical trials [10-13].
Despite high efficacy observed among treatment experi-
enced patients with drug resistance to other antiretroviral
drug classes, low genetic barrier to resistance and possible
cross-resistance among integrase inhibitors is a limiting fac-
tor in the practical use of these compounds. Virologic fail-
ure has been associated with major, signature mutations
within the catalytic domain of the enzyme, and include
Y143R/C, N155H Q148K/R/H integrase sequence variants
associated with significant susceptibility reduction both to
RAL and elvitegravir (EVG) [14-19]. Accumulation of sec-
ondary, accessory mutants is responsible for the further in-
crease in the level of the resistance and often restored
replication capacity [20-22]. Major mutations remain un-
common in the antiretroviral treatment naive patients; so
far only a few cases of transmitted drug resistance (Q148H,
G140S and N155H mutations) have been described [23,24].
On the other hand, polymorphic mutations in the central
core domain positions have been observed in up to 34% of
the published sequences [25] and 56% of the patients with
recently acquired infection [26]; some of these naturally oc-
curring variants have been observed in patients failing ralte-
gravir and elvitegravir (L74M, T97A, S119G/R, E157Q,
G163K/R), with notable the frequency variation across the
subtypes [4,25,27-31]. Recent reports also describe high fre-
quency of the minority clades bearing major and accessory
mutations, however, clinical significance of this pre-existing
low level variability is yet to be determined [20,27,32]. Ana-
lyses for the secondary drug resistance are currently
included in the guidelines for the drug resistance testing
among individuals failing integrase containing treatment
[33]. This study was designed to investigate the sequence
variability in the integrase region with two objectives: firstly,
to characterize primary integrase resistance mutations
among the treatment naive and experienced patients with
no prior integrase inhibitor (InI) exposure; secondly to in-
vestigate the development of the InI drug resistance muta-




In this study HIV-1 integrase sequences from patients
observed at the Department of Infectious Diseases and
Hepatology Pomeranian Medical University, Szczecin,
Poland and Out-Patient’s Clinic of Acquired Immunodefi-
ciency, Regional Hospital, Szczecin Poland were obtained.
Bioethical committee approval (Bioethical Committee of the
Pomeranian Medical University, Szczecin, Poland, approval
number KB-0012/08/12) was obtained for this analysis.
Informed consent was provided and obtained from study
participants. Eighty samples from patients who have never
received the integrase inhibitors were selected, including
forty-six pretreatment ones from individuals who have later
received raltegravir (RAL). Additionally, sequences were
obtained at the time of virologic failure on RAL (HIV-RNA
levels analysed every four months), whenever such a failure
have occurred. Virologic failure was defined as two consecu-
tive viral loads >50 HIV RNA copies/ml. To assess adher-
ence number of dispensed monthly doses of antiretroviral
medication divided by the number of follow-up months,
expressed as a percentage, was used.
Sequencing
HIV RNA extraction was performed from plasma samples
stored at -80 degrees Centigrade using a reagents provided
with the Viroseq 2.8 kit (Abbott molecular, Abbott Park,
IL, USA). HIV-1 integrase region (866 base pair, HXB2
genome location: positions 4230-5096) was amplified and
sequenced with reagents and conditions specified by
Laethem et al., and the following amplification and se-
quencing primers: AGGAGCAGAAACTTWCTATGTA
GATGG (outer forward), TTCTTCCTGCCATAGGAR
ATGCCTAAG (outer reverse), TTCRGGATYAGAAG
TAAAYATAGTAACAG (inner forward), TCCTGTATG
CARACCCCAATATG (inner reverse and sequencing),
GCACAYAAAGGRATTGGAGGAAATGAAC (sequen-
cing, forward), GGVATTCCCTACAATCCCCAAAG (se-
quencing, forward), GAATACTGCCATTTGTACTGCTG
(sequencing, reverse) [34]. Amplicons obtained by the
nested PCR method were used for sequencing by standard
techniques with BigDye technology on an ABI 3500 plat-
form (Applied Biosystems, Foster City, CA). Sequence as-
sembly was performed with the Recall online tool (http://
pssm.cfenet.ubc.ca) [35]. For all the InI treated patients
both baseline (prior to the raltegravir treatment) and
on treatment (at the virologic failure) sequences were
obtained. As integrase region sequencing has been
initiated in 2011 majority of the samples have been ana-
lyzed retrospectively. Integrase sequencing in patients with
viral loads >50 copies/ml was attempted from every avail-
able sample, usually collected every four months. All
sequences were submitted to GenBank (accession num-
bers JQ305769-91, KC409134-KC409222).
Parczewski et al. BMC Infectious Diseases 2012, 12:368 Page 2 of 10
http://www.biomedcentral.com/1471-2334/12/368
Drug resistance, subtyping and phylogenetic analyses
Drug resistance mutations were called with Stanford DB
database (hivdb.stanford.edu) and grouped into major and
minor mutations as assigned by this on-line tool [36]. For
subtyping, phylogenetic analysis with reference sequences
listed in the HIV Sequence Compendium 2011 (Los Alamos
National Laboratory Los Alamos, USA http://www.hiv.lanl.
gov) was used. The sequence dataset was aligned with
Clustal X2.0.10 (www.clustal.org). GTR+I+γ substitution
model was selected with jmodeltest (software version 0.1.1)
based on the lowest akaike information criterion (AIC)
[37,38]. Base frequencies for the dataset were as follows:
A = 0.4036, C = 0.1613, G = 0.2272, T = 0.2079, p inv par-
ameter: 0.507, gamma shape: 0.76.
Bootstrapped (1000 replicates) maximum composite like-
lihood (ML) test under the GTR+I+γ model with three sep-
arate codon positions, and a nearest-neighbor-interchange
ML method was inferred using MEGA 5.05 software. Phyl-
ogeny obtained subtype was compared with an on-line sub-
typing performed by the Stanford DB database. For clarity,
phylogenetic trees were divided into subtype B and non
subtype B groups and visualized with the tree explorer
included in the MEGA software.
For analysis of the integrase resistance development
and phylogenetic relationships between the serially
obtained sequences from patients failing on raltegravir
containing treatment Bayesian Monte Carlo Marcov
Chain (MCMC) analyses were implemented. Two repli-
cates of 100 million generations were run in BEAST v
1.5.3 [39], under the GTR+γ+Γ model with estimated
base frequencies, gamma site heterogenity model, and
three partitions for the codon positions. A consensus
tree with posterior probabilities for branch support was
obtained and annotated with TreeAnnotator v 1.5.4.
Trees were visualized in Figtree v.1.2.2.
For nominal variables chi-square test with EPI6 Stat-
calc software was used (Department of Mathematics,
University of Louisiana-Lafayette, Lafayette, LA, USA),
while for continuous variables the Mann–Whitney




Majority of the analyzed patients were male, with HIV
infection acquired by the heterosexual transmission, with
clinical symptoms of immunodeficiency (either B or C
according to the CDC classification), baseline lympho-
cyte CD4 count below 200 cells/μl and HIV-1 viral load
exceeding 100 000 copies/ml (Table 1). Median age at
the diagnosis for the entire analysed group was 35 years
(IQR:27-45), and 37 years (IQR:26-43) for the RAL-
treated patients. In twenty cases integrase inhibitor
treatment was commenced at undetectable viral load,
due to the toxicity of the previous regimen, drug resist-
ance, liver failure or drug interactions.
Integrase sequencing was consistently successful at HIV
viral loads exceeding 300 copies/ml, and one sample of
134 HIV-RNA copies/ml. In two cases the sequencing
failed and subtype was unavailable; as the result final data-
set for the baseline integrase resistance included the group
of 78 individuals.
Subtypes and baseline drug resistance mutations
Majority of the integrase region sequences were classified
as subtype B; the remaining ones being subtype D, C, G,
and recombinants: CRF01_AE, CRF02_AG and CRF13_cpx
(Table 1, Figure 1A,B). For all but one sequence concord-
ance between the phylogenetic analysis and Stanford DB
assigned subtype was noted but CRF13_cpx recombinant
was called subtype J by this on-line tool. In the subtype B
infected group injection drug use associated infections were
the predominant transmission route (19 cases, 39.6%), fol-
lowed by the men who have sex with men (15 cases, 31.2%)
and heterosexual transmissions (13 cases, 27.1%). For one
subtype B infected patient the transmission route remains
unknown. For all non-B subtypes heterosexual exposure
was noted.
In the InI naive group no major integrase drug resist-
ance mutations have been observed, but in 30 (38.5%)
cases polymorphic variation with minimal influence on
integrase inhibitor susceptibility was found, being signifi-
cantly more common among subtype B sequences (26
cases, 54.2%) than non-B ones (5 cases, 16.7%), p=0.00099,
OR: 5.91 (95% CI:1.77-22.63) (Figure 1a, 1b). The predom-
inating E157Q polymorphism was found in 47.9% of the
subtype B sequences and associated with injection drug
use (69.6% of the sequences with E157Q were derived
from the IDU patients). This variant was absent in non-B
clades. Other mutations and polymorphisms observed
only in subtype B integrase sequences were L68V, T97A
and V151I, while in non-B sequences R263K, E138D,
L68IL and L74IL variants were noted (Figure 1b, Table 1).
Development of InI drug resistance
Of the RAL treated patients in twelve cases (26.1%) treat-
ment failure was observed, with borderline statistical associ-
ation with non-B subtype [p=0.098, OR: 3.13 (95% CI:0.
64-15.7)]. In the failing group estimated adherence ranged
from the 58% to 99%. In four cases (8.3% of the total num-
ber of patients treated with raltegravir, 33.3% of the failing
ones) major InI drug resistance mutations have been
observed. Mean viral load on raltegravir treatment in the
failing group was 2.79 (95% CI:2.35-3.22) log HIV-RNA
copies/ml being notably higher among patients with devel-
oped drug resistance [mean of 3.73 (95% CI:3.19-4.28) log
HIV-RNA copies/ml] compared to the failing ones without
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the InI drug resistance mutations [mean: 2.79 (95% CI:2.35
-3.22) log HIV-RNA copies/ml] (p=0.0079, Figure 2).
Baseline polymorphisms, including the most prevalent
E157Q analyzed separately, were not associated with
the virologic failure on RAL [p=0.5, OR 1.56 (95% CI:
0.35-7.11) and p=0.38, OR 1.83 (95% CI:0.38-10.05),
respectively]. In 14 cases with virologic success accessory
mutations were present prior to the raltegravir introduc-
tion (11 sequences with E157Q, one of each L68V/E157Q,
T97A, V151I). Among virologically failing patients E157Q
was noted in one patient with N155H mutant, in three
E157Q variant was present at baseline and consistently in
the sequences obtained on RAL therapy while in two
patients either R263K or L74IL were present at baseline
and disappeared in the subsequent sequences on virologic-
ally unsuccessful treatment.
Development of drug resistance mutations followed
two patterns: major N155H with or without subsequent
accessory V151I, E92EQ, V151I, G163R mutants (three
cases) and Q148H accompanied by G140S mutant (one
Table 1 Characteristics of the study population
Entire group (n=80)* Patients treated with raltegravir (n=46)
Female gender, n (%) 34 (42.5) 19 (41.3)
Transmission route
IDU, n (%) 19 (23.8) 13 (28.3)
Heterosexual, n (%) 43 (53.8) 22 (47.8)
MSM, n (%) 17 (21.3) 10 (21.7)
Unknown, n (%) 1 (1.3) 1 (2.2)
CDC category at HIV diagnosis
A , n (%) 23 (28.8) 14 (30.4)
B, n (%) 34 (42.5) 19 (41.3)
C, n (%) 22 (27.5) 14 (30.4)
Lymphocyte CD4 count at diagnosis, median cells/μl, (IQR) 147 (51-331) 140 (29-336)
Lymphocyte CD4 count prior to raltegravir introduction, median cells/μl (IQR) N.A. 335 (154-515)
HIV viral load at diagnosis, median log HIV-1 copies/ml (IQR) 5.33 ( 4.62-5.88) 5.38
(4.62-5.56)
HIV-RNA undetectable prior to raltegravir introduction, n (%) N.A. 20 (44)
HIV viral load prior to raltegravir introduction, median log HIV-1 copies/ml (IQR) N.A. 4.88 (3.36-5.44)
HIV-1 subtype (integrase coding region) *
B, n (%) 48 (61.5) 30 (68.2)
D , n (%) 24 (30.8) 10 (21.7)
C, n (%) 2 (2.6) 2 (4.5)
G, n (%) 1 (1.3) 0
CRF01_AE , n (%) 1 (1.3) 1 (2.3)
CRF02_AG, n (%) 1 (1.3) 1 (2.3)
CRF13_cpx , n (%) 1 (1.3) 0
Baseline integrase polymorphisms *
None , n (%) 48 (61.5) 24 (54.5)
E157Q , n (%) 23 (28.8) 15 (34.1)
V151I, n (%) 2 (3.1) 1 (2.3)
E138D, n (%) 2 (2.6) 0
T97A, n (%) 1 (1.3) 1 (2.3)
R263K, n (%) 1 (1.3) 1 (2.3)
L74IL, n (%) 1 (1.3) 1 (2.3)
L68V, n (%) 1 (1.3) 1 (2.3)
*in two cases of raltegravir treated patients the integrase coding region sequencing failed, thus the subtype and interpretation of the baseline integrase
polymorphisms was unavailable.
Table legend: IDU: injection drug use, MSM – men who have sex with men, IQR – interquartile range.
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case) (Figure 3B). To determine the intra-patient rela-
tionships between the mutations we have also used a
time-annotated phylogenetic Bayesian Monte Carlo
Marcov Chain analysis rooted with the pretreatment
samples (Figure 3A). Time to the development of drug
resistance ranged from the 2.6 to 16.3 months with
mean increase of the HIV viral load (available for
patients 1-3) of 4.34 (95% CI:1.86-6.84) log HIV-RNA
copies/ml at the time point of emergence of the major
drug resistance mutations.
It must be noted, that three of the patients with devel-
oped drug resistance were heavily experienced with re-
verse transcriptase (RT) and protease (PR) mutations
(patient 1: RT: M41L, K103N, M184V, T215S; PR: L10I;
patient 2: PR: M41L, V118I, K103N, M184V, L210W,
T215S, RT: L10I, M46I, I54V, L63P, A71T, V82A, L90M,
patient 4: RT: K103N, M184V, P225H, F227L), while one
patient (number 3) due to endocarditis and kidney fail-
ure was treated with live-saving but suboptimal therapy
which consisted solely of ritonavir-boosted saquinavir
and raltegravir.
Discussion
Integrase inhibitors remain an attractive option and have
become a vital component of the modern antiretroviral
treatment, especially among patients with preexisting
drug resistance or treatment complications [2,40-45]. It
is necessary to monitor the transmission and de novo de-
velopment of drug resistance mutations decreasing the
susceptibility of HIV against this class of antiretrovirals
to provide the virologists and clinicians with the current
data allowing for adequate therapeutic strategies.
In the presented study, among the InI naive patients
no major drug resistance mutations have been observed,
however, accessory mutations have been common
(38.5%). Of the noted variants, four (L68V, T97A, V151I,
E157Q) have previously been described as polymorphic,
occurring in >1% of integrase sequences [25]. These
integrase mutations were more prevalent in the subtype
B viruses with E157Q occurring at higher frequencies
than previously reported [46-50]. In the previous reports
this polymorphism was shown to impair the integrase
30end processing and strand transfer [17] but was asso-
ciated with only minimal reduction of the susceptibility
to RAL and elvitegravir (<6 fold) [25,26,51,52]. Of note,
in our study the E157Q mutation was observed mostly
among phylogenetically related subtype B infected intra-
venous drug users (Figure 1A), and was not associated
with higher ratio of the virological failure. This is the lar-
gest described so far cluster with this polymorphism in
subtype B infected patients. Lack of clinically important,
primary resistance mutations for raltegravir, elvitegravir
and dolutegravir is consistent with published reports
from other studies [27,47,53-59], and is supports the fact
(See figure on previous page.)
Figure 1 Maximum composite likelihood inferred trees showing phylogenetic relationships of subtype B (A) and non-subtype B
isolates to the HIV-1 M group reference strains. Bootstrap values, expressed as percentage, are listed at the branch nodes. Baseline integrase
mutations are listed alongside patient number following an asterisk.
Figure 2 HIV-1 viral loads in the group failing raltegravir containing treatment with and without observed InI drug resistance
mutations.



















































Figure 3 (See legend on next page.)
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that the transmission of the drug resistance is unlikely in
the populations previously unexposed to the integrase
inhibitor treatment [60].
In the group of the RAL treated patients treatment was
successful in 73.9% of cases, while the 8.3% of the failing
patients developed major drug resistance mutations signifi-
cantly reducing susceptibility to both raltegravir and elvite-
gravir. Number of virologic failures was higher than
observed in the STARTMRK and BENCHMRK trials for
the patients with high baseline genotypic scores [1,5,6,15],
however, in the analysed group integrase inhibitor was usu-
ally considered as a second line treatment and was selected
due to toxicity, drug resistance or drug-drug interactions,
as well as preexisting drug resistance in treatment experi-
enced patients; suboptimal adherence was also commonly
noted - only in three (one described below with developed
integrase resistance mutations and two with integrase-
inhibitor susceptible variants) failing patients estimated ad-
herence exceeded 90%. Another reason for the high fre-
quency of treatment failure on raltegravir-containing
regimen may be related to the preexisting drug resistance
mutations in the reverse transcriptase region resulting in
the lower susceptibility to the background regimen. NRTI
drug resistance mutations (thymidyne analog mutations
and M184V) were present in six (50%) of the twelve treat-
ment failing patients prior to RAL introduction. Addition-
ally, treatment efficacy was numerically worse among non-
B subtypes (with borderline statistical significance), how-
ever this may be associated with small group size as in the
previous reports raltegravir was comparably efficacious
across B and non-B HIV-1 subtypes [4].
Integrase drug resistance profiles in four treatment fail-
ing patients with drug resistance followed two typical path-
ways, Q148H/G140S (one case) and N155H/V151I (three
patients), associated with high level resistance to raltegravir
and cross-resistance to elvitegravir [16-18,61,62]. Similar
cases have been described previously [19,61,63]. Of note,
in the patient with the Q148H/G140S salvage treatment
option with dolutegravir was also lost due to the resistance
associated with this pathway [64]. As expected, in cases
observed in our study virologic rebound was associated
with significant increase of the plasma viral load at
the time-point of the occurrence of the major mutation.
Stepwise accumulation of mutations was observed in two
patients with N155H followed by the secondary E92Q,
V151I and/or G163R mutations resulting in further
increase raltegravir and elvitegravir resistance and often
enhanced replicative capacity [27,65]. All observed muta-
tions have been previously associated with raltegravir drug
resistance observed in in vivo studies [15,45]. The N155H
pathway is also associated with smaller reduction in the
RAL susceptibility than the Q148H, moreover, double
Q148H/G140S mutants were found to be fitter than the
E92Q/N155H ones [66,67]. This is consistent with the
observed higher viral loads at the time of the development
of drug resistance in a patient 2 (if compared to the
patients 1,3,4) in whom such a highly fit double mutant
was observed (Figure 3). In the patient 3 the observed drug
resistance is probably associated with the suboptimal treat-
ment and poor drug exposure when combined only with
boosted saqinavir, however no other treatment option was
possible for the patient at the time of therapy initiation .
Time to InI resistance development in the observed
patients did not exceed few months, except for one case
with the double Q148H/G140S mutant, which is in accord-
ance to the data on the low genetic barrier for the integrase
inhibitors and rapid selection of the resistant variants
[15,68].
Conclusions
In summary, the results of this study provide data for
the clinical practice and the treatment with integrase
inhibitors. No major mutations associated with integrase
dug resistance have been found in the pretreatment
samples, however the polymorphic variation was com-
mon. In the failing patients selection of drug resistance
occurred rapidly, and followed the typical pathways with
accumulation of the drug resistance. Poor adherence,
preexisting drug resistance and suboptimal combination
were the key reasons associated with the development of
the drug resistance.
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